Among non–pCR patients in the GeparTrio trial, patients with high residual tumor Ki67 had a higher risk of recurrence and death, whereas the survival of patients with low Ki67 did not differ significantly from that of pCR patients [37]. This evidence concerns the gene MKI67 and neoplasm.